# A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

> **NCT06864143** · PHASE2 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 1320 (actual)

## Conditions studied

- Influenza
- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** mRNA-1083 Composition 1 Dose A Lot A
- **BIOLOGICAL:** mRNA-1083 Composition 1 Dose A Lot B
- **BIOLOGICAL:** mRNA-1083 Composition 1 Dose B
- **BIOLOGICAL:** mRNA-1083 Composition 1 Dose C
- **BIOLOGICAL:** mRNA-1083 Composition 2 Dose A
- **BIOLOGICAL:** mRNA-1083 Composition 2 Dose B
- **BIOLOGICAL:** mRNA-1083 Composition 3 Dose A
- **BIOLOGICAL:** mRNA-1083 Composition 3 Dose B
- **BIOLOGICAL:** Influenza Vaccine
- **BIOLOGICAL:** COVID-19 Vaccine
- **BIOLOGICAL:** Investigational Influenza Vaccine
- **BIOLOGICAL:** Investigational COVID-19 Vaccine Lot A
- **BIOLOGICAL:** Investigational COVID-19 Vaccine Lot B

## Key facts

- **NCT ID:** NCT06864143
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-07
- **Primary completion:** 2025-10-13
- **Final completion:** 2025-10-13
- **Target enrollment:** 1320 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06864143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06864143, "A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06864143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*